Lene Ryom1, Jens D Lundgren1, Peter Reiss2,3, Mike Ross4, Ole Kirk1, Christophe A Fux5, Phillipe Morlat6, Eric Fontas7, Colette Smith8, Stephane De Wit9, Antonella d'Arminio Monforte10, Wafaa El Sadr11, Camilla Hatleberg1, Andrew Phillips8, Caroline Sabin8, Matthew Law12, Amanda Mocroft8. 1. Rigshospitalet, University of Copenhagen, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen, Denmark. 2. Amsterdam University Medical Centers (location AMC), Department of Global Health and Division of Infectious Diseases, University of Amsterdam, Amsterdam, The Netherlands. 3. HIV Monitoring Foundation, Amsterdam, The Netherlands. 4. Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA. 5. Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland. 6. Université de Bordeaux, Inserm U 897, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. 7. Department of Public Health, Nice University Hospital, Nice, France. 8. Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom. 9. Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium. 10. Dipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy. 11. ICAP-Columbia University and Harlem Hospital, New York, New York, USA. 12. Kirby Institute, University of New South Wales, Sydney, Australia.
Abstract
BACKGROUND: Relations between different measures of human immunodeficiency virus-related immunosuppression and chronic kidney disease (CKD) remain unknown. METHODS: Immunosuppression measures included baseline, current, time-lagged and nadir CD4, years and percentage of follow-up (%FU) with CD4 ≤200 cells/μL, and CD4 recovery. CKD was defined as confirmed estimated glomerular filtration rate <60 mL/minute/1.73 m2. RESULTS: Of 33 791 persons, 2226 developed CKD. Univariably, all immunosuppression measures predicted CKD. Multivariably, the strongest predictor was %FU CD4 ≤200 cells/μL (0 vs >25%; incidence rate ratio [IRR], 0.77 [95% confidence interval [CI], .68-.88]), with highest effect in those at low D:A:D CKD risk (IRR, 0.45 [95% CI, .24-.80]) vs 0.80 [95% CI, .70-.93]). CONCLUSIONS: Longer immunosuppression duration most strongly predicts CKD and affects persons at low CKD risk more.
BACKGROUND: Relations between different measures of human immunodeficiency virus-related immunosuppression and chronic kidney disease (CKD) remain unknown. METHODS: Immunosuppression measures included baseline, current, time-lagged and nadir CD4, years and percentage of follow-up (%FU) with CD4 ≤200 cells/μL, and CD4 recovery. CKD was defined as confirmed estimated glomerular filtration rate <60 mL/minute/1.73 m2. RESULTS: Of 33 791 persons, 2226 developed CKD. Univariably, all immunosuppression measures predicted CKD. Multivariably, the strongest predictor was %FU CD4 ≤200 cells/μL (0 vs >25%; incidence rate ratio [IRR], 0.77 [95% confidence interval [CI], .68-.88]), with highest effect in those at low D:A:D CKD risk (IRR, 0.45 [95% CI, .24-.80]) vs 0.80 [95% CI, .70-.93]). CONCLUSIONS: Longer immunosuppression duration most strongly predicts CKD and affects persons at low CKD risk more.
Authors: Chris T Longenecker; Douglas Kitch; Paul E Sax; Eric S Daar; Camlin Tierney; Samir K Gupta; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Judith Schouten; Ferdinand W Wit; Ineke G Stolte; Neeltje A Kootstra; Marc van der Valk; Suzanne E Geerlings; Maria Prins; Peter Reiss Journal: Clin Infect Dis Date: 2014-09-02 Impact factor: 9.079
Authors: N Petersen; A D Knudsen; A Mocroft; D Kirkegaard-Klitbo; E Arici; J Lundgren; T Benfield; P Oturai; B G Nordestgaard; B Feldt-Rasmussen; S D Nielsen; L Ryom Journal: HIV Med Date: 2019-07-29 Impact factor: 3.180
Authors: Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: Ditte M Kirkegaard-Klitbo; Niels Mejer; Troels B Knudsen; Holger J Møller; Søren K Moestrup; Susanne D Poulsen; Gitte Kronborg; Thomas Benfield Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: A C Achhra; A Mocroft; M J Ross; L Ryom; G M Lucas; H Furrer; J Neuhaus; C Somboonwit; M Kelly; J M Gatell; C M Wyatt Journal: HIV Med Date: 2015-04 Impact factor: 3.180
Authors: A Mocroft; H J Furrer; J M Miro; P Reiss; C Mussini; O Kirk; S Abgrall; S Ayayi; B Bartmeyer; D Braun; A Castagna; A d'Arminio Monforte; B Gazzard; F Gutierrez; I Hurtado; K Jansen; L Meyer; P Muñoz; N Obel; P Soler-Palacin; A Papadopoulos; F Raffi; J T Ramos; J K Rockstroh; D Salmon; C Torti; J Warszawski; S de Wit; R Zangerle; C Fabre-Colin; J Kjaer; G Chene; J Grarup; J D Lundgren Journal: Clin Infect Dis Date: 2013-08-06 Impact factor: 9.079
Authors: Rebecca Scherzer; Monica Gandhi; Michelle M Estrella; Phyllis C Tien; Steven G Deeks; Carl Grunfeld; Carmen A Peralta; Michael G Shlipak Journal: AIDS Date: 2014-06-01 Impact factor: 4.177
Authors: Birgit Grund; Jason V Baker; Steven G Deeks; Julian Wolfson; Deborah Wentworth; Alessandro Cozzi-Lepri; Calvin J Cohen; Andrew Phillips; Jens D Lundgren; James D Neaton Journal: PLoS One Date: 2016-05-12 Impact factor: 3.240